Workshop Reading Getting Started Read the following selections in Pharmacotherapeutics for Advanced

Workshop Reading
Getting Started
Read the following selections in Pharmacotherapeutics for Advanced Practice Nurses and Physicians Assistants:
Antipsychotic Agents and Their Use in Schizophrenia (Chapter 26)
Schizophrenia: Clinical presentation and etiology, p. 203-04, Table 26.1
First-generation (conventional) antipsychotics, p. 204-10, Tables 26.2-4
Second-generation (Atypical) antipsychotics, p. 210-11, Tables 26.2-4
Depot antipsychotic preparations, p. 211-12, Table 26.5
Management of schizophrenia, p. 212-13
Antidepressants (Chapter 27)
Major depression: clinical features, pathogenesis, and treatment overview, p. 214
Drugs used for depression, p. 214-26, Tables 27.1-5, Figures 27.1-3
Peripartum depression, p. 226-27
Drugs for Bipolar Disorder (Chapter 28)
Characteristics of bipolar disorder, p. 228
Treatment of Bipolar disorder, p. 229-30, Table 28.1
Mood-stabilizing drugs, p. 230-33, Tables 28.2-4
Antipsychotic drugs, p. 233
Sedative-Hypnotic Drugs (Chapter 29)
Benzodiazepines, p. 234-37, Table 29.1
Benzodiazepine-like drugs, p. 237-38, Table 29.2
Ramelteon: a melatonin agonist, p. 238, Table 29.2
Suvorexant: an orexin antagonist, p. 239, Table 29.2
Barbiturates, p. 239-40, Figure 29.1
Management of insomnia, p. 240-41, Table 29.3
Other hypnotics, p. 241-42
Management of Anxiety Disorders (Chapter 30)
Generalized anxiety disorders, p. 243-44, Tables 30.1-2
Panic disorder, p. 244-45, Tables 30.1-2
Obsessive-compulsive disorder, p. 245-46, Tables 30.1-2
Social anxiety disorder, p. 246, Tables 30.1-2
Post-traumatic stress disorder, p. 246-47, Tables 30.1-2
Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder (Chapter 31)
Central nervous system stimulants, p. 248-50, Table 31.1
Attention-Deficit Hyperactivity Disorder, p. 250-53, Table 31.1
Drugs of Abuse I: Basic Considerations (Chapter 32)
Definitions, p. 255-56
Diagnostic criteria for substance use disorder, p. 256
Factors that contribute to substance abuse disorder, p. 256-57
Neurobiology of addiction, p. 257
Principles of substance use disorder treatment, p. 257, Box 32.1
Controlled substances act, p. 257-59, Table 32.1
Drug Abuse II: Alcohol (Chapter 33)
Basic pharmacology of alcohol, p. 260-63
Alcohol use disorder, p. 263-64, Table 33.1
Drugs for alcohol use disorder, p. 264-66, Tables 33.2-3
Drug Abuse IV: Major Drugs of Abuse Other Than Alcohol and Nicotine (Chapter 35)
Heroin, oxycodone, and other opioids, p. 273-75, Tables 35.1-2
Kratom, p. 275-76
General central nervous system depressants, p. 276, Table 35.1
Psychostimulants, p. 276-78, Table 33.1
Marijuana and related preparations, p. 278-81, Tables 33.1 and 33.3
Psychedelics, p. 281-82, Table 35.1
Dextromethorphan, p. 282, Table 33.1
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy), p. 282-83, Table 33.1
Inhalants, p. 283
Use the treatment guidelines/recommendations associated with Workshop 3 as resources for all assignments with focus on the treatment sections.